Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide effervescent tablets for maintenance of remission in adult eosinophilic esophagitis
NL-OMON47207Phase 3Active, not recruiting
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Sep 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of budesonide in eosinophilic esophagitis (EoE) (3 arms), sponsored by Dr. Falk Pharma GmbH. Primary endpoint: Rate of patients free of treatment failure after 48 weeks. Started Sep 2016; status: active, not recruiting.
02
Drugs
budesonide
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NL-OMON47207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47207.